These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 9024823

  • 1. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
    Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N.
    J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823
    [Abstract] [Full Text] [Related]

  • 2. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.
    Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N.
    Gene Ther; 2000 Mar; 7(6):518-26. PubMed ID: 10757026
    [Abstract] [Full Text] [Related]

  • 3. Suppression of various human tumor cell lines by a dominant negative H-ras mutant.
    Ogiso Y, Sakai N, Watari H, Yokoyama T, Kuzumaki N.
    Gene Ther; 1994 Nov; 1(6):403-7. PubMed ID: 7584106
    [Abstract] [Full Text] [Related]

  • 4. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
    Yokoyama T.
    Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
    [Abstract] [Full Text] [Related]

  • 5. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.
    Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y, Takahashi T, Okushiba S, Takimoto M, Kato H, Kuzumaki N.
    Int J Cancer; 1998 Oct 29; 78(3):366-71. PubMed ID: 9766573
    [Abstract] [Full Text] [Related]

  • 6. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B, He Y, Sun DL, Zou Y, Qin XH, Huang BH.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 22; 88(28):1956-60. PubMed ID: 19062734
    [Abstract] [Full Text] [Related]

  • 7. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.
    Tsuchida T, Kijima H, Hori S, Oshika Y, Tokunaga T, Kawai K, Yamazaki H, Ueyama Y, Scanlon KJ, Tamaoki N, Nakamura M.
    Cancer Gene Ther; 2000 Mar 22; 7(3):373-83. PubMed ID: 10766343
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J, Ouyang ZG, Zhang SH, Zhen YS.
    Oncol Rep; 2007 Jun 22; 17(6):1445-51. PubMed ID: 17487403
    [Abstract] [Full Text] [Related]

  • 10. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
    Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M.
    Mol Carcinog; 1997 Oct 22; 20(2):251-8. PubMed ID: 9364215
    [Abstract] [Full Text] [Related]

  • 11. Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA.
    Lu GR, Wu CJ, Ke Y, Xiong X, Li YJ, Liu JM, Xu Y, Xu W, Li JY, Deng GR.
    Sci China B; 1991 Dec 22; 34(12):1485-91. PubMed ID: 1801843
    [Abstract] [Full Text] [Related]

  • 12. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells.
    Zhu Z, Kleeff J, Kayed H, Wang L, Korc M, Büchler MW, Friess H.
    Mol Carcinog; 2002 Nov 22; 35(3):138-47. PubMed ID: 12410565
    [Abstract] [Full Text] [Related]

  • 13. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells.
    Tsuchida T, Kijima H, Oshika Y, Tokunaga T, Abe Y, Yamazaki H, Tamaoki N, Ueyama Y, Scanlon KJ, Nakamura M.
    Biochem Biophys Res Commun; 1998 Dec 18; 253(2):368-73. PubMed ID: 9878544
    [Abstract] [Full Text] [Related]

  • 14. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
    Kanovsky M, Michl J, Botzolaki G, Morin J, Kovac C, Chung DL, Chie L, Friedman FK, Pincus MR.
    Cancer Chemother Pharmacol; 2003 Sep 18; 52(3):202-8. PubMed ID: 12783204
    [Abstract] [Full Text] [Related]

  • 15. Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model.
    Yanagie H, Tanabe T, Sumimoto H, Sugiyama H, Matsuda S, Nonaka Y, Ogiwara N, Sasaki K, Tani K, Takamoto S, Takahashi H, Eriguchi M.
    Biomed Pharmacother; 2009 May 18; 63(4):275-86. PubMed ID: 18657378
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
    Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW.
    Cancer Res; 2006 Oct 01; 66(19):9736-43. PubMed ID: 17018633
    [Abstract] [Full Text] [Related]

  • 17. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
    Nakano M, Aoki K, Matsumoto N, Ohnami S, Hatanaka K, Hibi T, Terada M, Yoshida T.
    Mol Ther; 2001 Apr 01; 3(4):491-9. PubMed ID: 11319909
    [Abstract] [Full Text] [Related]

  • 18. Molecular target-based therapy of pancreatic cancer.
    Lebedeva IV, Sarkar D, Su ZZ, Gopalkrishnan RV, Athar M, Randolph A, Valerie K, Dent P, Fisher PB.
    Cancer Res; 2006 Feb 15; 66(4):2403-13. PubMed ID: 16489047
    [Abstract] [Full Text] [Related]

  • 19. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation.
    Abe M, Yamashita J, Ogawa M.
    Cancer; 2000 May 01; 88(9):2000-9. PubMed ID: 10813710
    [Abstract] [Full Text] [Related]

  • 20. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K, Park S, Ewton DZ, Friedman E.
    Cancer Res; 2007 Aug 01; 67(15):7247-55. PubMed ID: 17671193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.